NCT05374278 is a Phase 1, PHASE2 clinical trial of [18F]RP-115 PET/MRI or PET/CT and MRI in Alzheimer Disease, sponsored by David Wilson.

Who is sponsoring NCT05374278?

NCT05374278 is sponsored by David Wilson.

What drugs are being tested in NCT05374278?

Interventions in NCT05374278: [18F]RP-115 PET/MRI or PET/CT and MRI.

What condition does NCT05374278 study?

NCT05374278 studies Alzheimer Disease, Frontotemporal Dementia, Dementia.

Is NCT05374278 still recruiting?

NCT05374278 is currently recruiting now. Last updated 17 April 2025.

Last reviewed 2025-04-17 · How we verify

NCT05374278

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

First-in-Human Evaluation of an Astrocytic Glutamate Transporter (EAAT2) PET Tracer in Dementia

Recruiting now Phase 1, PHASE2 Last updated 17 April 2025

What this trial tests

Phase 1, PHASE2 trial testing [18F]RP-115 PET/MRI or PET/CT and MRI in Alzheimer Disease in 102 participants. Currently enrolling.

Timeline

2 November 2021

Primary endpoint
3 April 2027

31 May 2027

Quick facts

Lead sponsor	David Wilson
Phase	Phase 1, PHASE2
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	102
Start date	2 November 2021
Primary completion	3 April 2027
Estimated completion	31 May 2027
Sites	1 location across United States

Drugs / interventions tested

[18F]RP-115 PET/MRI or PET/CT and MRI — full drug profile →

Conditions studied

Alzheimer Disease — all drugs for Alzheimer Disease →
Frontotemporal Dementia — all drugs for Frontotemporal Dementia →
Dementia — all drugs for Dementia →

Sponsor

David Wilson — full company profile →

Who can join

Adults 40 to 75, any sex, with Alzheimer Disease or Frontotemporal Dementia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a first in human study that will assess the safety and diagnostic performance of \[18F\]RP-115 (fluorine-18 labeled RP115), a positron emission tomography (PET) agent. This agent has the potential to identify the early changes that occur in the brains of patients with Alzheimer's disease (AD) and frontotemporal dementia (FTD).

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

A Medicinal Chemistry Perspective on Excitatory Amino Acid Transporter 2 Dysfunction in Neurodegenerative Diseases.
Fontana IC, Souza DG, Souza DO, Gee A, et al · · 2023 · cited 23× · PMID 36787643 · DOI 10.1021/acs.jmedchem.2c01572
Activity and Heterogeneity of Astrocytes in Neurological Diseases: Molecular Mechanisms and Therapeutic Targets.
Mao S, Qiao R, Wang Q, Shen L, et al · · 2025 · cited 1× · PMID 40859959 · DOI 10.1002/mco2.70329
First-in-human healthy volunteer dosimetry studies of the excitatory amino acid transporter 2 (EAAT2) PET imaging tracer methyl N4-(7-[18F]fluoro-9H-fluoren-2-yl)asparaginate, [18F]RP-115.
Chao CK, Blecha J, Polvoy I, Nillo RM, et al · · 2025 · cited 1× · PMID 39913962 · DOI 10.1016/j.nucmedbio.2025.108992

Verify or expand the search:

Other recruiting trials for Alzheimer Disease

Currently open trials in the same condition.

NCT07290387 — Tele-Savvy for Latino Caregivers · NA · recruiting
NCT07178210 — Robotic-Enabled Microsurgical Intervention for Neurodegenerative Disease · NA · recruiting
NCT07294885 — Deep Cervical LymphatIc-Venous Anastomosis for Alzheimer's Disease · NA · recruiting
NCT06937229 — A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3) · Phase 3 · recruiting
NCT06930560 — HEARS-NPS: Addressing Hearing Loss as a Common Unmet Contributor of Neuropsychiatric Symptoms · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05374278 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 9 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by David Wilson
Last refreshed: 17 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05374278.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing